Document is current
Any future updates will be listed below
-
Authors
Ayala, Edgardo F. Cartagena
Colon, Lumen Vera
Aydinok, Yesim
Arboleda-Osorio, Bolívar
Bracey, Arthur
Fasano, Ross
Yee, Marianne
Sarode, Ravindra
Zubair, Abba C.
Nizzi, Frank
Shah, Sanjay
Snyder, Edward L.
Treml, Angela
Zheng, Yan
Takemoto, Clifford
Green, Jeffrey
Jackson, Bryon
Pitman, John P.
Gniadek, Thomas J.
Liu, Kathy
Bentow, Stanley
Corash, Laurence
Mufti, Nina
Benjamin, Richard J.
- License Information
-
More Information
Article History
Received: 28 January 2026
Accepted: 17 May 2026
First Online: 26 May 2026
Declarations
Ethics approval and consent to participate: The RedeS study (CLI 00126 v9.0) has been approved by the WCG IRB, most recently on 16 January 2025 (IRB Tracking Number: 20162905) and by multiple institutional review boards. Written, informed consent to participate will be obtained from all participants.
Consent for publication: Informed consent was obtained for publication of anonymized patient data at the time of patient consent for enrollment.
Competing interests: RJB, KL, SB, JPP, TJG, NM, and LC are employees and shareholders of Cerus Corporation, the Sponsor of the study. YA has received research funding from Cerus, Bristol Myers Squibb (BMS), Agios, Novartis, and Sobi, and has served as a consultant for Vertex, BMS, Agios, and Chiesi. All other co-authors are site investigators on the study receive no compensation from the Sponsor and declare no conflicts relating to the study.
